Dapagliflozin improves podocytes injury in diabetic nephropathy via regulating cholesterol balance through KLF5 targeting the ABCA1 signalling pathway.
Journal Information
Full Title: Diabetol Metab Syndr
Abbreviation: Diabetol Metab Syndr
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Subject Category: Endocrinology & Metabolism
Available in Europe PMC: Yes
Available in PMC: Yes
PDF Available: No
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Declarations Ethics approval and consent to participateThe present study was approved by the Animal Ethics Committee of Shandong Provincial Hospital, affiliated with Shandong First Medical University. There are no human subjects in this article and informed consent is not applicable. Consent for publicationNot applicable. Competing interestsThe authors declare no competing interests. Competing interests The authors declare no competing interests."
"Funding This study was supported in part by grants from the National Natural Science Foundation of China to Ying Xu (81500553) and to Qinglian Wang (82100791). This study was also supported by Natural Science Foundation of Shandong Province to Qinglian Wang (ZR2021QH137) and to Ying Xu(ZR2022MH041)."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025